Welcome to Life lines, the second report in Reed Smith’s Deal Dimensions series
Life lines explores the main drivers behind the avid pursuit for cross-border life sciences deals, the challenges faced in executing those deals, and how advances in personalised medicine may change the face of the industry.
Key findings include:
In Q2 2015, Mergermarket surveyed 100 senior executives (CEO, CIO, Director of Strategy) in biotechnology and pharmaceuticals companies.
The respondents were evenly split across the US (34%), Europe (33%) and Asia (33%).
The representation by company size is $100m-1bn (34%), $1bn-5bn (33%) and $5bn+ (33%).
The survey consisted of a combination of qualitative and quantitative questions and all interviews were conducted over the phone by appointment. Results were analysed and collated by Mergermarket and all responses are anonymised and presented in aggregate.
The research is complemented by interviews with Reed Smith’s senior practitioners conducted by Mergermarket.